Literature DB >> 1998965

Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

T Mukhopadhyay1, M Tainsky, A C Cavender, J A Roth.   

Abstract

A human lung cancer cell line (H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a 2-kilobase genomic segment of the K-ras protooncogene in antisense orientation. Translation of the mutated K-ras mRNA in H460a cells was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A 3-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA. However, cells remained viable despite the absence of K-ras expression. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998965

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Gene therapy in lung cancer.

Authors:  S G Swisher; J A Roth
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Therapeutic genes for cancer gene therapy.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

Review 4.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

5.  Chemoprevention of tea on colorectal cancer induced by dimethylhydrazine in Wistar rats.

Authors:  Xu-Dong Jia; Chi Han
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

6.  Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene.

Authors:  M E Rosenfeld; S M Vickers; D Raben; M Wang; L Sampson; M Feng; E Jaffee; D T Curiel
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

7.  K-ras mutations in patients with early colorectal cancers.

Authors:  H J Andreyev; J V Tilsed; D Cunningham; S A Sampson; A R Norman; H J Schneider; P A Clarke
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

8.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

Review 9.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.